Gossamer Bio Decline Means Insider Profits Down To US$17k [Yahoo! Finance]
Gossamer Bio, Inc. (GOSS)
Last gossamer bio, inc. earnings: 3/24 07:00 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
After taking the recent loss into consideration, the US$138.1k worth of stock they bought is now worth US$155.4k, indicating that their investment yielded a positive return. While insider transactions are not the most important thing when it comes to long-term investing, logic dictates you should pay some attention to whether insiders are buying or selling shares. Check out our latest analysis for Gossamer Bio Gossamer Bio Insider Transactions Over The Last Year In the last twelve months, the biggest single purchase by an insider was when COO & CFO Bryan Giraudo bought US$113k worth of shares at a price of US$0.56 per share. We do like to see buying, but this purchase was made at well below the current price of US$0.67. While it does suggest insiders consider the stock undervalued at lower prices, this transaction doesn't tell us much about what they think of current prices. Happily, we note that in the last year insiders paid US$138k for 232.00k shares. But insiders sold 45
Show less
Read more
Impact Snapshot
Event Time:
GOSS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GOSS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GOSS alerts
High impacting Gossamer Bio, Inc. news events
Weekly update
A roundup of the hottest topics
GOSS
News
- Chiesi and Gossamer Bio Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in Pulmonary Arterial Hypertension and Other Respiratory IndicationsPR Newswire
- Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other Indications [Yahoo! Finance]Yahoo! Finance
- Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other IndicationsBusiness Wire
- Gossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory Medicine [Yahoo! Finance]Yahoo! Finance
- Gossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory MedicineBusiness Wire
GOSS
Earnings
- 11/9/23 - Miss
GOSS
Sec Filings
- 5/6/24 - Form 8-K
- 4/26/24 - Form ARS
- 4/24/24 - Form DEFA14A
- GOSS's page on the SEC website